Efficacy and safety of perampanel in patients with seizures associated with Lennox–Gastaut syndrome: A randomized trial
Epilepsia · 2025-02 · 66 (2) · 379-393
DOI: 10.1111/epi.18193 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 22.11.2024. Verfasst von David G Vossler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Pyridones, Anticonvulsants, Lennox Gastaut Syndrome, Seizures. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Inc., Eisai Ltd., and Eisai Co., Ltd., Eisai Canada.
Abstract (Originalsprache)
Objectives
The Phase 3 Study 338 (NCT02834793) assessed long‐term clinical outcomes of adjunctive perampanel in patients ≥2 years of age with uncontrolled seizures associated with Lennox–Gastaut syndrome (LGS).
Methods
Eligible patients were diagnosed with LGS and receiving one to four concomitant antiseizure medications with an average of two or more drop seizures/week during baseline. The study comprised an 18‐week double‐blind, randomized, placebo‐controlled Core Study and ≥52‐week open‐label Extension. The primary endpoint was median percent change in drop seizure frequency per 28 days during the Core Study. Key secondary endpoints included responder rates, seizure‐freedom rates, and safety outcomes. Post hoc analyses were performed encompassing a broader range of drop seizures or all countable motor seizures.
Results
Seventy patients were randomized into the Core Study (perampanel, n = 34; placebo, n = 36), and 58 entered the Extension. In the Core Study, numerically greater median percent reductions in drop seizure frequency were observed with perampanel (23.1%) vs placebo (4.5%) using prespecified assessments ( p = .107), whereas significantly greater reductions were detected using the broader definition (48.6% vs −.7%, respectively, p = .001) or all countable motor seizures (44.0% vs −.6%, respectively, p = .017). The 50% responder rate for drop seizures was higher with perampanel vs placebo using modern definitions. Reductions in seizure frequency with perampanel were maintained over 52 weeks. Treatment‐emergent adverse events occurred in 85.3% of perampanel‐treated patients (somnolence [23.5%] was the most frequent) and 72.2% of placebo‐treated patients. Significance This study had a reduced sample size and was underpowered. Although the difference in reductions in drop seizure frequency between treatments was not statistically significant by prespecified assessments, adjunctive perampanel demonstrated sustained efficacy in reducing drop seizures associated with LGS for ≤71 weeks using modern definitions. No new safety signals emerged. These observations suggest the long‐term efficacy and safety of perampanel in the LGS population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA.
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California, USA.
- Department of Pediatric Neurology, Fukuoka Children's Hospital, Fukuoka, Japan.
- Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Pediatric Neurology, Hôpital Universitaire Des Enfants Reine Fabiola and Hôpital Erasme-Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
- BRACE consortium (Brussels Rare and Complex Epilepsies), EpiCare-European Reference Network (ERN), Brussels, Belgium.
ORCID-Profile: David G Vossler, Brenda E Porter, Ryutaro Kira, Jeehun Lee, Alec Aeby, Anna Patten, Jocelyn Y Cheng, Leock Y Ngo
Förderung
- Eisai Inc., Eisai Ltd., and Eisai Co., Ltd.
- Eisai Canada
Zitieren
APA
Vossler, D. G., Porter, B. E., Kira, R., Lee, J., Aeby, A., Patten, A., Cheng, J. Y., Ngo, L. Y., & 338 Study Investigators (2025). Efficacy and safety of perampanel in patients with seizures associated with Lennox–Gastaut syndrome: A randomized trial. Epilepsia, 66(2), 379-393. https://doi.org/10.1111/epi.18193
Vancouver
Vossler DG, Porter BE, Kira R, Lee J, Aeby A, Patten A, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox–Gastaut syndrome: A randomized trial. Epilepsia. 2025;66(2):379-393. doi:10.1111/epi.18193
BibTeX
@article{Vossler2025,
author = {Vossler, David G and Porter, Brenda E and Kira, Ryutaro and Lee, Jeehun and Aeby, Alec and Patten, Anna and Cheng, Jocelyn Y and Ngo, Leock Y and 338 Study Investigators, 338 Study Investigators},
title = {Efficacy and safety of perampanel in patients with seizures associated with Lennox–Gastaut syndrome: A randomized trial},
journal = {Epilepsia},
year = {2025},
volume = {66},
number = {2},
pages = {379--393},
doi = {10.1111/epi.18193}
}
EUVIMED